Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to demonstrate that V181 is safe and well tolerated and elicits an immune response that is non-inferior to that of Butantan-DV at Day 28 post-vaccination in adults 18 to 50 years of age in Brazil. The primary hypothesis is that V181 is non-inferior to Butantan-DV for each of the 4 dengue serotypes based on geometric mean titers (GMTs) and seroconversion rates at Day 28 post-vaccination.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male participants are eligible to participate if they agree to the following for at least 90 days after administration of study intervention:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
Is dengue seronegative based on a pre-vaccination point of care (POC) dengue test.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,364 participants in 2 patient groups
Loading...
Central trial contact
Toll Free Number
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal